BioCentury | Nov 7, 2013
Translation in Brief

Translational tidbits

...antibody against IL-16 to treat inflammatory diseases and ischemic reperfusion injury Agilent Technologies Inc. (NYSE:A) Seoul National University Hospital...
BioCentury | Oct 28, 2013
Company News

Agilent, Seoul National University Hospital deal

...details, and the university could not be reached. Agilent Technologies Inc. (NYSE:A), Santa Clara, Calif. Seoul National University Hospital...
BioCentury | Apr 11, 2013
Cover Story

RET, set, go

...compounds in RET fusion-positive lung cancer. AstraZeneca is working with two groups, one based at Seoul National University Hospital...
...Switzerland Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), South San Francisco, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Seoul National University Hospital...
...collaborator Clinical trial record RET fusions Caprelsa vandetanib Non-small cell lung cancer (NSCLC) Phase II Seoul National University Hospital...
Items per page:
1 - 3 of 3
BioCentury | Nov 7, 2013
Translation in Brief

Translational tidbits

...antibody against IL-16 to treat inflammatory diseases and ischemic reperfusion injury Agilent Technologies Inc. (NYSE:A) Seoul National University Hospital...
BioCentury | Oct 28, 2013
Company News

Agilent, Seoul National University Hospital deal

...details, and the university could not be reached. Agilent Technologies Inc. (NYSE:A), Santa Clara, Calif. Seoul National University Hospital...
BioCentury | Apr 11, 2013
Cover Story

RET, set, go

...compounds in RET fusion-positive lung cancer. AstraZeneca is working with two groups, one based at Seoul National University Hospital...
...Switzerland Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), South San Francisco, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Seoul National University Hospital...
...collaborator Clinical trial record RET fusions Caprelsa vandetanib Non-small cell lung cancer (NSCLC) Phase II Seoul National University Hospital...
Items per page:
1 - 3 of 3